Showing posts with label multiple myeloma. Show all posts
Showing posts with label multiple myeloma. Show all posts
Wednesday, January 13, 2016

Takeda receives FDA approval for NINLARO (ixazomib) capsules to treat patients with multiple myeloma

›
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the U.S. Food and Drug Administration (FDA) has approved NINLAR...
Tuesday, July 30, 2013

Phase III study: REVLIMID meets primary endpoint in patients newly diagnosed with multiple myeloma

›
In continuation of my update on  lenalidomide Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ: C...
Saturday, August 11, 2012

Three-drug regimen provides rapid, durable responses for multiple myeloma

›
In continuation of my update on three drug combination A three-drug treatment for the blood cancer multiple myeloma provided rapid, d...
Thursday, December 15, 2011

Combination of bortezomib and panobinostat shows promise against advanced multiple myeloma

›
In co\continuation of  my update on Bortezomib... A phase 2 clinical trial has shown that pairing bortezomib with an experimental drug,...
Monday, August 9, 2010

Impressive Results of Velcade(R) (bortezomib) Based Therapy in Multiple Myeloma...

›
 In continuation of my update on Bortezomib [ 1 , 2 ] The Takeda Oncology Company today reported new correlative science data fr...
Tuesday, December 22, 2009

New three-drug combination for multiple myeloma ! ...

›
The regimen, known as RVD , combined the drugs Revlimid - ( lenalidomide ), Velcade - ( bortezomib ) and dexamethasone , which previously we...
Friday, December 11, 2009

Carfilzomib for multiple myeloma ?

›
The proteasome has emerged as an important target for cancer therapy with the approval of bortezomib , a first-in-class, reversible prote...